Diseases & Conditions
Grants & Contracts
News & Events
The ChemDB database contains information extracted from scientific literature on the structure and activity of compounds that have been tested against HIV, opportunistic pathogens and TB.
This contract provides gap-filling support services for HIV prevention drug developers including academic (investigators), for-profit and not-for-profit small and large companies, and other product innovators (henceforth identified as Sponsors) for the development of HIV non-vaccine biomedical pr
The RSC Public Website, run by the DAIDS Regulatory Support Center (RSC) contractor, has been used in the DAIDS community for over 10 years and is a primary platform to communicate updates to templates, process changes, and other information needed by the RSC research community.
Repository of specimens collected as part of the DAIDS VAX004 Clinical Trial.
The Feasibility of Novel Diagnostics for TB in Endemic Countries (FEND for TB) program supports the evaluation of early-stage diagnostics and novel diagnostic strategies for TB, in TB endemic countries to address an urgent need for improved tuberculosis (TB) diagnostics.
The HIV Database & Analysis Unit provides an integrated repository of HIV sequence and immunology published data, by curating & maintaining a relational database with searchable web access for the scientific community; and (ii) develop web-based computation analysis methods and tools for
This service can be used to develop and perform a variety of analytical assays to assess the properties of drug substances and their formulations.
This service provides follow-up studies of products which already have been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development of the product as an HIV therapeutic.
This service provides evaluation of products in animal efficacy models. A product must demonstrate a potent and selective activity profile in vitro against the HIV strain used in the model prior to its acceptance as a candidate for this service.
This service can be used to provide pharmacokinetic and safety assessments of products in mice, rats, rabbits, dogs, and nonhuman primates.
This service program supports the development and manufacture, of a wide variety of pharmaceutical dosage formulations, including tablets, capsules, semi-solid preparations, injectibles, and sustained-release products. If requested, manufacturing can be done under GMP.
The HVTN shares data and specimens collected in its studies with investigators who would like to use our materials to answer research questions related to vaccinology, immunology, or HIV/AIDS.
HVTN provides structured mentorship and project funding to investigators working on HIV vaccines.
This service provides chemical synthesis of lead compounds for use in additional drug development studies. Compounds must previously have been successfully synthesized to be candidates for this service. Synthesis of new analogs is not supported.
This service provides evaluation of products that have already been evaluated in a biochemical or cell-based assay and shown to possess an activity profile that warrants further development as a microbicide.
The Multicenter AIDS Cohort Study (MACS) is an ongoing prospective study of the natural and treated histories of HIV-1 infection in homosexual and bisexual men conducted by sites located in Baltimore, Chicago, Pittsburgh and Los Angeles.
The National Institutes of Health (NIH) HIV Reagent Program provides critical research reagents and resources to the scientific community.
The Preclinical Development Support Master Contract (PDSMC) supports all phases of preclinical development, including process and product development, GMP manufacturing and clinical lot production, analytical and formulation, preclinical enabling studies and associated tasks leading to the filing
The Process Development and Analytical Support Contract (PAS) supports two key critical components: process development and analytical characterization activities.
This contract is with the International Aids Vaccine Initiative (IAVI).
The SVEU provides the nonhuman primates for studies to evaluate candidate SIV or HIV vaccines.